The physiologic anticoagulant and anti-inflammatory role of heparins and their utility in the prevention of pregnancy complications

Summary

Accumulating evidence supports the concept of increased thrombin generation, placental vascular lesions, and inflammation as crucial points in the development of the great obstetrical syndromes [preeclampsia, intrauterine growth restriction (IUGR), preterm labor (PTL), preterm prelabor rupture of membranes (PROM), fetal demise and recurrent abortions]. In light of this, the role of heparins for primary or secondary prevention of these syndromes is becoming more and more apparent, mainly due to the antithrombotic and anti-inflammatory effects of heparins. There is agreement regarding the use of heparin in the prevention of gestational complications in patients with antiphospholipid syndrome, while its use for other obstetrical complications is under debate. In the present review we will describe the physiologic role of heparins on coagulation and inflammation and we will discuss current evidence regarding the use of heparins for the prevention/ treatment of obstetrical syndromes.

Keywords

Antiphospholipid syndrome - inflammation - preterm labour - recurrent pregnancy loss - thrombin generation

• References

• 1 Erez O. et al. The Activity of the Natural Initiator of Coagulation-Tissue Factor, But Not That of Its Pathway Inhibitor, is Elevated in Women with Preeclampsia and SGA: A Potential Explanation for the Excessive Thrombin Generation in These Syndromes. Annual Scientific Meeting of the Society for Gynecologic Investigation, Glasgow, Scotland, March 17-21, 2009.. J Soc Gynecol Investig 2009. Poster presentation, Abstract 351.
• 2 Kupferminc MJ. et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 2001; 20: 35-44.
• 3 Carp H. et al. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003; 01: 433-438.
• 4 Marcum JA. et al. Anticoagulantly active heparin-like molecules from mast celldeficient mice. Am J Physiol 1986; 250: H879-H888.
• 5 Nader HB. et al. Heparan sulfates and heparins: similar compounds performing the same functions in vertebrates and invertebrates?. Braz J Med Biol Res 1999; 32: 529-538.
• 6 Rosenberg RD. et al. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Commun 1979; 86: 1319-1324.
• 7 Björk I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982; 48: 161-182.
• 8 Petitou M. et al. Synthesis of heparin fragments: a methyl alpha-pentaoside with high affinity for antithrombin III. Carbohydr Res 1987; 167: 67-75.
• 9 Petitou M. et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540). J Med Chem 1997; 40: 1600-1607.
• 10 Chang CH. et al. Synthesis of the Heparin-Based Anticoagulant Drug Fondaparinux. Angew Chem Int Ed Engl 2014; 53: 9876-9879.
• 11 Koenig A. et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101: 877-889.
• 12 Skinner MP. et al. GMP-140 binding to neutrophils is inhibited by sulfated glycans. J Biol Chem 1991; 266: 5371-5374.
• 13 Kishimoto TK. et al. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science 1989; 245: 1238-1241.
• 14 Diamond MS. et al. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol 1995; 130: 1473-1482.
• 15 Watt SM. et al. The heparin binding PECAM-1 adhesion molecule is expressed by CD34+ hematopoietic precursor cells with early myeloid and B-lymphoid cell phenotypes. Blood 1993; 82: 2649-2663.
• 16 Wang XF. et al. Low molecular weight heparin relieves experimental colitis in mice by downregulating IL-1β and inhibiting syndecan-1 shedding in the intestinal mucosa. PLoS One 2013; 08: e66397.
• 17 Götte M. Syndecans in inflammation. FASEB J 2003; 17: 575-591.
• 18 Li X. et al. Unfractionated heparin ameliorates lipopolysaccharide-induced lung inflammation by downregulating nuclear factor-κB signaling pathway. Inflammation 2013; 36: 1201-1208.
• 19 Gaffney A, Gaffney P. Rheumatoid arthritis and heparin. Br J Rheumatol 1996; 35: 808-809.
• 20 Fine NL. et al. Objective evaluation of heparin in the treatment of asthma. Am Rev Respir Dis 1968; 98: 886-887.
• 21 Ahmed T. et al. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 1993; 329: 90-95.
• 22 Tyrell DJ. et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999; 46: 151-208.
• 23 Romero R. Prenatal medicine: the child is the father of the man. 1996. J Matern Fetal Neonatal Med 2009; 22: 636-639.
• 24 Erez O. et al. Evidence of maternal platelet activation, excessive thrombin generation, and high amniotic fluid tissue factor immunoreactivity and functional activity in patients with fetal death. J Matern Fetal Neonatal Med 2009; 22: 672-687.
• 25 Erez O. et al. High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor. J Matern Fetal Neonatal Med 2010; 23: 23-33.
• 26 Galli M, Barbui T. Antiphospholipid antibodies and thrombosis: strength of association. Hematol J 2003; 04: 180-186.
• 27 Cohen D. et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol 2011; 225: 502-511.
• 28 Yamada H. et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol 2009; 79: 188-195.
• 29 Beeksma FA. et al. Placental fetal vascular thrombosis lesions and maternal thrombophilia. Pathology 2012; 44: 24-28.
• 30 Wells M. et al. Complement component deposition in uteroplacental (spiral) arteries in normal human pregnancy. J Reprod Immunol 1987; 12: 125-135.
• 31 Cunningham DS, Tichenor JR. Decay-accelerating factor protects human trophoblast from complement-mediated attack. Clin Immunol Immunopathol 1995; 74: 156-161.
• 32 Tedesco F. et al. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol 1993; 151: 1562-1570.
• 33 Liszewski MK. et al. Control of the complement system. Adv Immunol 1996; 61: 201-283.
• 34 Salmon JE, Girardi G. Theodore E. Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammation. Trans Am Clin Climatol Assoc 2007; 118: 99-114.
• 35 Girardi G. et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644-1654.
• 36 Girardi G, Mackman N. Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule. Lupus 2008; 17: 931-936.
• 37 Fouda UM. et al. Efficacy and safety of two doses of low molecular weight heparin (enoxaparin) in pregnant women with a history of recurrent abortion secondary to antiphospholipid syndrome. J Obstet Gynaecol 2010; 30: 842-846.
• 38 Brenner B. et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000; 83: 693-697.
• 39 Sinauridze EI. et al. Anticoagulant therapy: basic principles, classic approaches and recent developments. Blood Coagul Fibrinolysis 2012; 23: 482-493.
• 40 Guerin J. et al. Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome. J Biol Chem 2002; 277: 2644-2649.
• 41 Wagenknecht DR, McIntyre JA. Interaction of heparin with beta 2-glycoprotein I and antiphospholipid antibodies in vitro. Thromb Res 1992; 68: 495-500.
• 42 Franklin RD, Kutteh WH. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol 2003; 101: 455-462.
• 43 Ermel LD. et al. Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL). Am J Reprod Immunol 1995; 33: 14-20.
• 44 Di Simone N. et al. Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. Hum Reprod Update 2007; 13: 189-196.
• 45 Distler JH. et al. Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum 2005; 52: 3337-3348.
• 46 Di Simone N. et al. Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid- mediated defective placentation. Arthritis Rheum 2010; 62: 1504-1512.
• 47 Mulla MJ. et al. Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity. Am J Reprod Immunol 2010; 63: 339-348.
• 48 Bose P. et al. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol 2004; 191: 2125-2131.
• 49 Bose P. et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 2005; 192: 23-30.
• 50 Giles IP. et al. A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs. Semin Arthritis Rheum 2003; 32: 246-265.
• 51 Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002; 41: 391-412.
• 52 Giles I. et al. Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. J Immunol 2006; 177: 1729-1736.
• 53 Frank M. et al. Effects of low-molecular-weight heparin on adhesion and vesiculation of phospholipid membranes: a possible mechanism for the treatment of hypercoagulability in antiphospholipid syndrome. Ann NY Acad Sci 2009; 1173: 874-886.
• 54 Prinz N. et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood 2011; 118: 2322-2332.
• 55 Redecha P. et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110: 2423-2431.
• 56 Ecker E, Gross P. Anticomplementary power of heparin. J Infect Dis 1929; 44: 250.
• 57 Girardi G. et al. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222-1226.
• 58 Oberkersch R. et al. Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res 2010; 125: e240-e245.
• 59 Alalaf S. Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipd antibody syndrome. Arch Gynecol Obstet 2012; 285: 641-647.
• 60 Ziakas PD. et al. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010; 115: 1256-1262.
• 61 Rai R. et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-257.
• 62 Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-1589.
• 63 Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial. Am J Obstet Gynecol 1997; 176: 1099-1100.
• 64 Tulppala M. et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Hum Reprod 1997; 12: 1567-1572.
• 65 Pattison NS. et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000; 183: 1008-1012.
• 66 Stephenson MD. et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004; 26: 729-734.
• 67 Noble LS. et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005; 83: 684-690.
• 68 Fouda UM. et al. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. Int J Gynaecol Obstet 2011; 112: 211-215.
• 69 Wu CQ. et al. The medical management of antiphospholipid syndrome in pregnancy: a meta-analysis. Obstet Gynecol 2014; 123 (Suppl. 01) 178S-179S.
• 70 Jaslow CR. Uterine Factors. Obstet Gynecol Clin North Am 2014; 41: 57-86.
• 71 Rajcan-Separovic E. et al. Identification of copy number variants in miscarriages from couples with idiopathic recurrent pregnancy loss. Hum Reprod 2010; 25: 2913-2922.
• 72 Ke RW. Endocrine Basis for Recurrent Pregnancy Loss. Obstet Gynecol Clin North Am 2014; 41: 103-112.
• 73 Kwak-Kim J. et al. Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome. Am J Reprod Immunol 2013; 69: 596-607.
• 74 Lino FL. et al. Thrombophilic Mutations and Polymorphisms, Alone or in Combination, and Recurrent Spontaneous Abortion. Clin Appl Thromb Hemost. 2014. Epub ahead of print.
• 75 Langer R. et al. Adjuvant anticoagulant therapy in repeated fetal loss. Harefuah 1980; 99: 65-67.
• 76 Lindqvist PG, Merlo J. The natural course of women with recurrent fetal loss. J Thromb Haemost 2006; 04: 896-897.
• 77 Brenner B. et al. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost 2005; 03: 227-229.
• 78 Robertson L. et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171-196.
• 79 Dolitzky M. et al. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006; 86: 362-366.
• 80 Clark P. et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010; 115: 4162-4167.
• 81 Kaandorp SP. et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362: 1586-1596.
• 82 Visser J. et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost 2011; 105: 295-301.
• 83 Di Nisio M. et al. Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome. Cochrane Database Syst Rev 2005; CD004734.
• 84 Gris JC. et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-3699.
• 85 Folkeringa N. et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol 2007; 136: 656-661.
• 86 Martinelli I. et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 2012; 119: 3269-3275.
• 87 Kupferminc MJ. Thrombophilia and pregnancy. Reprod Biol Endocrinol 2003; 01: 111.
• 88 Redline RW. et al. Placental diagnostic criteria and clinical correlation--a workshop report. Placenta 2005; 26 Suppl A S114-S117.
• 89 Kupferminc M. et al. Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagul Fibrinolysis 2011; 22: 123-126.
• 90 Rey E. et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 07: 58-64.
• 91 Gris JC. et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost 2010; 104: 771-779.
• 92 Mello G. et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005; 45: 86-91.
• 93 Gris JC, Mares P. The long and winding road ... towards LMWH for pregnancy loss. J Thromb Haemost 2005; 03: 224-226.
• 94 Leduc L. et al. Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. J Obstet Gynaecol Can 2007; 29: 787-793.
• 95 De Vries JI. et al. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2012; 10: 64-72.
• 96 Scifres CM, Macones GA. The utility of thrombophilia testing in pregnant women with thrombosis: fact or fiction?. Am J Obstet Gynecol 2008; 199 (344) e1-e7.
• 97 Abou-Nassar K. et al. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial. Thromb Haemost 2007; 98: 163-171.
• 98 Dodd JM. et al. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2013; 07: CD006780.
• 99 Tomer A. et al. Antiphospholipid antibody syndrome: the flow cytometric annexin A5 competition assay as a diagnostic tool. Br J Haematol 2007; 139: 113-120.
• 100 Stephenson MD, Ballem PJ, Tsang P. et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can 2004; 26: 729-734.
• 101 Noble LS, Kutteh WH, Lashey N. et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005; 83: 684-690.
• 102 Fouda UM, Sayed AM, Abdou AM. et al. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. Int J Gynaecol Obstet 2011; 112: 211-215.
• 103 Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408-413.
• 104 Laskin CA, Spitzer KA, Clark CA. et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36: 279-287.
• 105 Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-1589.
• 106 Rai R, Cohen H, Dave M. et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-257.
• 107 Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Med Sci Monit 2006; 12: CR132-CR136.